Preliminary Review of APPROVe data –
Background
package for February, 2005 AC meeting.
Sponsor: Merck
Reviewer: Lourdes Villalba, M.D., MO, HFD-550
Jim Witter, M.D., Ph.D., Team Leader, HFD-550
1. Background:
Merck withdrew Vioxx from the market on
2. Results of APPROVe as presented to FDA on
APPROVe compared Rofecoxib 25mg vs. Placebo in approximately 2600 patients with a
history of colonic polyps. It had a 3-Year on-drug Treatment Period with a
one-year follow up period. Colonoscopies were done at screening, 1 year and 3
years on-drug, with a follow up colonoscopy at year 4 (1 year off-therapy) to
assess rebound. The mean age of patients
was 59 years (30% >65 years) and 60% were male. Of note, 15% were taking low
dose aspirin for cardiovascular prophylaxis. The study had an ESMB that met
regularly every 6 months. Cardiovascular adverse events were referred to an
independent CV adjudication committee that evaluated the cases in a blinded
manner. At the
Table 1. Confirmed CV thrombotic events
in APPROVe
Table 2. Confirmed CV/thrombotic
endpoints by aspirin use
Table
3. APTC composite endpoints by
aspirin use
It is unclear why the
denominator is different for Tables 2 and 3. Clarification is pending.
Figure 1. Time to Event Plot. Confirmed CV/Thrombotic events in APPROVe
A- placebo;
B- rofecoxib 25 mg
There was approximately twice
the number of cardiovascular thrombotic events in
patients receiving rofecoxib 25 mg as compared to
placebo. Results were consistent in any way one looked at them: all investigator reported CV/T events (data not shown), confirmed
CV/T events (Table 1 and 2) or APTC events (Table 3). As per Figure 1., the hazard ratio for CV/T events for rofecoxib
and placebo increased after 18 months of exposure, however, it is unclear
whether the rate in rofecoxib increased over time or
the rate in placebo made a plateau. (Analyses of risk over time are pending at
the time of this review.)
Reviewer’s
comments:
Some cardiologists have criticized FDA and
suggested that a clinical trial to address cardiovascular issues with COX-2
selective agents should have been conducted in patients at high cardiovascular
risk. However, such population with 100% use of low dose aspirin could
potentially require huge number of patients in studies of longer duration in
order to observe significant differences in cardiovascular events between
treatment groups.
3.
Review of analyses of CV/T events in relation to BP changes in APPROVe.
The Sponsor conducted several analyses of CV/T events in relation to
BP. Some of these analyses are included
in this review. As seen in Table 4. CV/T events are more common among those
patients with baseline blood pressure above DBP of 90 or SBP of 140 mmHg.
However, the relative risk of CV/T events for Vioxx
as compared to placebo, is consistently elevated among those patients with
normal and even low baseline blood pressure (RR = 1.5 to 3.5).
Table 4. Patients with investigator reported thromboembolic
or APTC events (excluding non-CV deaths) by baseline BP in APPROVe.
Baseline BP |
Placebo Events/patient years
(rate x 100 pt years) |
Rofecoxib 25 mg Events/patient years (rate x 100 pt years) |
Relative risk |
|
N= 1299 |
N= 1287 |
|
DBP≥100 or
SBP≥ 160 |
5/189 (2.7) |
7/176 (4.0) |
1.524 |
DPB 90-99 or SBP
140-159 |
19/1026 (1.9) |
26/846 (3.1) |
1.660 |
DBP 85-89 or SBP
130-139 |
14/704 (2.0) |
23/746 (3.1) |
1.555 |
DBP 80-84 or SBP
120-129 |
4/808 (0.5) |
12/705 (1.7) |
3.433 (p<0.05) |
DBP <80 and SBP
<120 |
2/547 (0.4) |
6/546 (1.1) |
3.159 |
(From
Sponsor’s Table 10.d. of
Table 5. Patients with investigator
reported thromboembolic or APTC events (excluding non
CV deaths) by on-treatment Hypertension in APPROVe.
On treatment HTN |
Placebo Events/patient years
(rate x 100 pt years) |
Rofecoxib 25 mg Events/patient years (rate x 100 pt years) |
Patients without HTN
|
32/2510 (1.3) |
35/2058 (1.7) |
Patients with HTN
(twice or more) |
8/381 ( 2.1) |
18/520 (3.5) |
n=events. * Hypertension
defined as patients with DBP ≥ 100 or DBP ≥ 160 mm Hg twice or
more. (From Sponsor’s
Table 11.d. of
Table 5 suggests that the rate of investigator reported CV/T or APTC
events is greater among patients who had hypertension during the study (as
defined by DBP ≥ 100 or DBP ≥ 160 mm Hg in two or more
measurements) for both, the rofecoxib and placebo
groups as compared to those who did not develop hypertension, and that more
patients developed hypertension in the rofecoxib
group as compared to placebo. However,
the relative risk of CV/T events is greater in the rofecoxib
group as compared to placebo, regardless of hypertension status.
Reviewer’s comment: This
observation suggests that while hypertension is important, there may be another
mechanism to explain the different rate of CV/T events between rofecoxib and placebo in this study.
Another possibility is that
increase in blood pressure, even if not as marked as DBP ≥ 100 or SBP
≥ 160 mm Hg may have an effect in increasing the risk of CV/T
events. Data from the
Additional analyses in patients who
develop borderline HTN (defined as DBP ≥ 90 or SBP ≥ 140 mm Hg) and
in patients taking concomitant antihypertensive medications (by different
categories of anti-hypertensive) are pending at the time of this review.